No Data
No Data
Zhejiang Tianyu Pharmaceutical (300702.SZ) has obtained pharmaceutical registration certificates for folic acid tablets, candesartan cilexetil and hydrochlorothiazide tablets, and Dapagliflozin tablets.
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced on July 5th that its wholly-owned subsidiary Zhejiang Nuo De Pharmaceutical Co., Ltd. (referred to as 'Nuo De Pharmaceutical') recently received the 'Drug Registration Certificate' approved and issued by the National Medical Products Administration (NMPA) for folic acid tablets, candesartan cilexetil tablets, and saxagliptin tablets.
Zhejiang Tianyu Pharmaceutical (SZSE:300702) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Zhejiang Tianyu Pharmaceutical (300702.SZ): The convertible bonds issuance plan to unspecified objects is expired and invalid.
On July 3, Gelonhui reported that as of the date of this announcement, the company's plan to issue convertible bonds to unspecified entities has expired and become invalid. The expiration of the company's plan to issue convertible bonds to unspecified entities will not have a significant impact on its operation. In the future, the company will formulate corresponding capital market financing plans based on its global strategy and funding needs. If the company has new refinancing plans in the future, it will promptly perform the relevant review procedures and information disclosure obligations in accordance with the relevant regulations, and investors are reminded to pay attention to investment risks.
Zhejiang Tianyu Pharmaceutical (300702.SZ): Nod Pharmaceuticals' empagliflozin tablets have been approved.
On June 25th, Gelonhui reported that Tianyu Pharmaceutical (300702.SZ), a wholly-owned subsidiary of the company, recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the Englejian Tablets. Englejian Tablets are a sodium-glucose cotransporter 2 (SGLT-2) inhibitor used to treat type 2 diabetes and heart failure in adults. The Englejian Tablets (10mg, 25mg) of Tianyu Pharmaceutical obtained acceptance from the State Drug Administration in February 2023. As of the end of May 2024, the company and its subsidiaries had accumulated research on the product.
Tianyu Co., Ltd. (300702.SZ): Empagliflozin API passed CDE review
Gelonghui, May 31 | Tianyu Co., Ltd. (300702.SZ) announced that the company's englicin API recently passed the review by the Drug Evaluation Center of the State Drug Administration (“CDE”). Empagliflozin tablets can be used to treat type 2 diabetes. The company submitted a drug registration application for englizin APIs to the CDE in December 2022 and was accepted. Empagliflozin APIs have now passed the CDE review, and the GMP compliance test results from the Zhejiang Drug Administration must be announced as “meeting the requirements” before they can be marketed and sold domestically.
Tianyu Co., Ltd. (300702.SZ) 2023 equity distribution: 0.5 yuan for every 10 shares, share registration on June 5
Tianyu Co., Ltd. (300702.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
No Data